Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent and certainother related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.

from News: Today’s News update from The Hindu | The Hindu https://ift.tt/Btck0V7